Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938282511> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2938282511 endingPage "S126" @default.
- W2938282511 startingPage "S126" @default.
- W2938282511 abstract "ICD is a prerequisite for induction of patient-specific protective immunity against tumor antigens. We hypothesize that the efficacy of Extracorporeal photochemotherapy (ECP) in initiating anti-lymphoma tumor specific immunity is traceable to its efficient induction of ICD in cutaneous T cell lymphoma (CTCL) malignant cells following their lethal exposure to photoactivated 8-methoxysporalen (8-MOPA). We tested that premise in a standard animal ICD vaccination assay, in three murine solid tumor models (sB16-OVA melanoma, YUMMER melanoma and MC38 colon cancer). Selective immunoprotection against subsequent challenge with viable relevant or control malignant cells was assessed after initial introduction of the same malignant cells rendered apoptotic by 8-MOPA. Vaccination with 8-MOPA pretreated tumor cells prevented B16-OVA melanoma in 77% (17% controls, n=60, p<0.0001), YUMMER 1.7 melanoma in 80% (0% controls, n=10, p<0.0016) and MC38 colorectal cancer in 90% (10% controls, n=20, p=0.0002). These high protection levels compare favorably to the most effective experimental ICD-inducing agents reported to date. Cell surface expression of calreticulin (CRT), a hallmark feature of ICD, was progressively increased on 8-MOPA exposed B16-OVA melanoma cells from background 2% to 19.7%, 44.8% and 46.8% by 24, 48 and 72 hrs post-treatment, as determined by flow cytometry. Proof of CRT’s role in the induction of this ICD was established by elimination of the immunoprotective effect through CRT knockdown in the “immunizing” 8-MOPA-treated B16-OVA line. These findings support the premise that 8-MOPA’s efficacy in initiating immunoprotective cancer cell ICD is a key element underlying ECP’s capacity to immunize against established tumors. The immunoprotective efficacy of 8-MOPA in three different experimental solid tumor systems, together with its established role in human lymphoma, suggest broad anti-cancer applicability of this approach." @default.
- W2938282511 created "2019-04-25" @default.
- W2938282511 creator A5048960746 @default.
- W2938282511 creator A5051291515 @default.
- W2938282511 creator A5071827163 @default.
- W2938282511 creator A5087517744 @default.
- W2938282511 creator A5087962191 @default.
- W2938282511 date "2019-05-01" @default.
- W2938282511 modified "2023-10-18" @default.
- W2938282511 title "733 Potent immunogenic cell death (ICD) caused by UVA-Activated 8-Methoxypsoralen (8-MOPA)" @default.
- W2938282511 doi "https://doi.org/10.1016/j.jid.2019.03.809" @default.
- W2938282511 hasPublicationYear "2019" @default.
- W2938282511 type Work @default.
- W2938282511 sameAs 2938282511 @default.
- W2938282511 citedByCount "1" @default.
- W2938282511 countsByYear W29382825112022 @default.
- W2938282511 crossrefType "journal-article" @default.
- W2938282511 hasAuthorship W2938282511A5048960746 @default.
- W2938282511 hasAuthorship W2938282511A5051291515 @default.
- W2938282511 hasAuthorship W2938282511A5071827163 @default.
- W2938282511 hasAuthorship W2938282511A5087517744 @default.
- W2938282511 hasAuthorship W2938282511A5087962191 @default.
- W2938282511 hasBestOaLocation W29382825111 @default.
- W2938282511 hasConcept C147483822 @default.
- W2938282511 hasConcept C158617107 @default.
- W2938282511 hasConcept C203014093 @default.
- W2938282511 hasConcept C2777658100 @default.
- W2938282511 hasConcept C2777701055 @default.
- W2938282511 hasConcept C2777877232 @default.
- W2938282511 hasConcept C47450691 @default.
- W2938282511 hasConcept C502942594 @default.
- W2938282511 hasConcept C553184892 @default.
- W2938282511 hasConcept C55493867 @default.
- W2938282511 hasConcept C71924100 @default.
- W2938282511 hasConcept C86803240 @default.
- W2938282511 hasConcept C8891405 @default.
- W2938282511 hasConceptScore W2938282511C147483822 @default.
- W2938282511 hasConceptScore W2938282511C158617107 @default.
- W2938282511 hasConceptScore W2938282511C203014093 @default.
- W2938282511 hasConceptScore W2938282511C2777658100 @default.
- W2938282511 hasConceptScore W2938282511C2777701055 @default.
- W2938282511 hasConceptScore W2938282511C2777877232 @default.
- W2938282511 hasConceptScore W2938282511C47450691 @default.
- W2938282511 hasConceptScore W2938282511C502942594 @default.
- W2938282511 hasConceptScore W2938282511C553184892 @default.
- W2938282511 hasConceptScore W2938282511C55493867 @default.
- W2938282511 hasConceptScore W2938282511C71924100 @default.
- W2938282511 hasConceptScore W2938282511C86803240 @default.
- W2938282511 hasConceptScore W2938282511C8891405 @default.
- W2938282511 hasIssue "5" @default.
- W2938282511 hasLocation W29382825111 @default.
- W2938282511 hasOpenAccess W2938282511 @default.
- W2938282511 hasPrimaryLocation W29382825111 @default.
- W2938282511 hasRelatedWork W1974496092 @default.
- W2938282511 hasRelatedWork W2010844627 @default.
- W2938282511 hasRelatedWork W2067632426 @default.
- W2938282511 hasRelatedWork W2081566357 @default.
- W2938282511 hasRelatedWork W2086322810 @default.
- W2938282511 hasRelatedWork W2283970331 @default.
- W2938282511 hasRelatedWork W2986983311 @default.
- W2938282511 hasRelatedWork W3167973226 @default.
- W2938282511 hasRelatedWork W4308770385 @default.
- W2938282511 hasRelatedWork W4377224671 @default.
- W2938282511 hasVolume "139" @default.
- W2938282511 isParatext "false" @default.
- W2938282511 isRetracted "false" @default.
- W2938282511 magId "2938282511" @default.
- W2938282511 workType "article" @default.